AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea · Delayed Price · Currency is KRW 4,495.00
-175.00 (-3.75%)
Nov 13, 2026, 3:30 PM KST
AptaBio Therapeutics Revenue
AptaBio Therapeutics had revenue of 1.60B KRW in the quarter ending June 30, 2026, with 42.81% growth. This brings the company's total for the last twelve months to 4.75B, up 52.91% year-over-year. In the year 2025, AptaBio Therapeutics had annual revenue of 3.70B with 10.02% growth. That makes AptaBio Therapeutics the 40,989th largest company in the world by revenue and 2,528th in South Korea.
Revenue (ttm)
4.75B
Revenue Growth
+52.91%
P/S Ratio
26.57
Revenue / Employee
108.03M
Employees
44
Market Cap
126.28B
Revenue by Segment
- Objectivo Business Division - Product Sales (General) 2.17B 58.7%
- New Business Division - Product Sales (ODM) 1.43B 38.8%
- New business division - Product Sales (General) 48.73M 1.3%
- Research and Development Department - Reagent Sales 44.29M 1.2%
Fiscal year ended Dec 31, 2025 See the full AptaBio Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.70B | 336.93M | 10.02% |
| Dec 31, 2024 | 3.36B | 3.04B | 937.76% |
| Dec 31, 2023 | 323.87M | 275.52M | 569.80% |
| Dec 31, 2022 | 48.35M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.